Welcome to our dedicated page for Marizyme SEC filings (Ticker: MRZM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Marizyme's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Marizyme's regulatory disclosures and financial reporting.
Marizyme, Inc. approved and executed a general assignment for the benefit of creditors, transferring all or substantially all of its assets to an assignee. On April 9, 2026, the Board determined this assignment was in the company’s best interests and authorized an Assignment Agreement with Peter Hurwitz as assignee, which was signed on April 14, 2026. The company states this transaction constitutes an assignment for the benefit of creditors proceeding under Chapter 727, Florida Statutes, and it is reported under the Bankruptcy or Receivership and Disposition of Assets items.